However, as of my last knowledge update in January 2022, Tazemetostat has been granted accelerated approval by the US Food and Drug Administration (FDA) for the treatment of metastatic or locally advanced epithelioid sarcoma in adults and pediatric patients aged 16 years of age and older.1
References
1Sabour-Takanlou M, Sabour-Takanlou L, Biray-Avci C. EZH2-associated tumor malignancy: A prominent target for cancer treatment. Clinical Genetics. Published online June 17, 2024. doi:10.1111/cge.14576